<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39407649</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Exploration of Specific Fluoroquinolone Interaction with SARS-CoV-2 Main Protease (Mpro) to Battle COVID-19: DFT, Molecular Docking, ADME and Cardiotoxicity Studies.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4721</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules29194721</ELocationID><Abstract><AbstractText>Herein, the pharmacokinetic profiles, binding interactions, and molecular properties of fluoroquinolone derivatives as prospective antiviral drugs are examined using a combination of docking, ADME, and DFT simulations. The effectiveness of the ligands is compared with the clinically tested and FDA-authorized medicine remdesivir. The findings demonstrated encouraging binding energies, indicating possible inhibitory effectiveness against SARS-CoV-2 M<sup>pro</sup>. The fluoroquinolone derivatives also exhibit promising ADME characteristics, although compounds 5, 6, 9, 12-20 possess poor values, suggesting that oral administration may be possible. The potential of the selected compounds as SARS-CoV-2 M<sup>pro</sup> inhibitors is thoroughly understood because of the integrated analysis of DFT, with compound 11 demonstrating the highest energy gap of 0.2604 eV of, docking with viral targets with docking scores of -7.9 to -5.9 kcal/mol, with compound 18 demonstrating the highest docking score, which is at the 13th position in energy difference in the DFT data. Their favorable electrical properties, robust binding interactions with viral targets, and attractive pharmacokinetic profiles boost their potential as prospective study subjects. These substances have the potential to be transformed into cutting-edge antiviral therapies that specifically target SARS-CoV-2 M<sup>pro</sup> and related coronaviruses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Muhammad Asim</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-7683-0102</Identifier><AffiliationInfo><Affiliation>School of Chemistry and Chemical Engineering, Linyi University, Linyi 276000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mutahir</LastName><ForeName>Sadaf</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4126-602X</Identifier><AffiliationInfo><Affiliation>School of Chemistry and Chemical Engineering, Linyi University, Linyi 276000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariq</LastName><ForeName>Muhammad Atif</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Sialkot, Sialkot 51300, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almehizia</LastName><ForeName>Abdulrahman A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0001-8711-3873</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z6124019</GrantID><Agency>Linyi University</Agency><Country /></Grant><Grant><GrantID>RSPD2024R852</GrantID><Agency>King Saud University</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086782">Coronavirus 3C Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024841">Fluoroquinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="Y">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086782" MajorTopicYN="Y">Coronavirus 3C Proteases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024841" MajorTopicYN="Y">Fluoroquinolones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077318" MajorTopicYN="N">Density Functional Theory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066126" MajorTopicYN="N">Cardiotoxicity</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ADME</Keyword><Keyword MajorTopicYN="N">DFT</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 Mpro</Keyword><Keyword MajorTopicYN="N">cardiotoxicity</Keyword><Keyword MajorTopicYN="N">fluoroquinolones</Keyword><Keyword MajorTopicYN="N">molecular docking</Keyword><Keyword MajorTopicYN="N">theoretical studies</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39407649</ArticleId><ArticleId IdType="pmc">PMC11477632</ArticleId><ArticleId IdType="doi">10.3390/molecules29194721</ArticleId><ArticleId IdType="pii">molecules29194721</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jebril N.M.T. World Health Organization declared a pandemic public health menace: A systematic review of the coronavirus disease 2019 “COVID-19”. SSRN Electron. J. 3566298. 2020 doi: 10.2139/ssrn.3566298.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3566298</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucinotta D., Vanelli M. WHO declares COVID-19 a pandemic. Acta. Biomed. 2020;91:157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsergouli K., Karampatakis T., Haidich A., Metallidis S., Papa A. Nosocomial infections caused by Crimean–Congo haemorrhagic fever virus. J. Hosp. Infect. 2020;105:43–52. doi: 10.1016/j.jhin.2019.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2019.12.001</ArticleId><ArticleId IdType="pubmed">31821852</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02145</ArticleId><ArticleId IdType="pmc">PMC7095016</ArticleId><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M., Yang J., Sun Y., Su G. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Chin. J. Tuberc. Respir. Dis. 2020;43:E014.</Citation><ArticleIdList><ArticleId IdType="pubmed">32061198</ArticleId></ArticleIdList></Reference><Reference><Citation>Batiha G.E.-S., Moubarak M., Shaheen H.M., Zakariya A.M., Usman I.M., Rauf A., Adhikari A., Dey A., Alexiou A., Hetta H.F. Favipiravir in SARS-CoV-2 Infection: Is it Worth it? Comb. Chem. High Throughput Screen. 2022;25:2413–2428. doi: 10.2174/1386207325666220414111840.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1386207325666220414111840</ArticleId><ArticleId IdType="pubmed">35430987</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L., Peng C. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–293. doi: 10.1038/s41586-020-2223-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2223-y</ArticleId><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId><ArticleId IdType="pmc">PMC7054408</ArticleId><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Islam M.S., Wang J., Li Y., Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective. Int. J. Biol. Sci. 2020;16:1708. doi: 10.7150/ijbs.45538.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.45538</ArticleId><ArticleId IdType="pmc">PMC7098036</ArticleId><ArticleId IdType="pubmed">32226288</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Zhang Y. Traditional Chinese medicine treatment of COVID-19. Complement. Ther. Clin. Pract. 2020;39:101165. doi: 10.1016/j.ctcp.2020.101165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctcp.2020.101165</ArticleId><ArticleId IdType="pmc">PMC7118627</ArticleId><ArticleId IdType="pubmed">32379692</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampaio F., Sequeira C., Teixeira L. Impact of COVID-19 outbreak on nurses’ mental health: A prospective cohort study. Environ. Res. 2021;194:110620. doi: 10.1016/j.envres.2020.110620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2020.110620</ArticleId><ArticleId IdType="pmc">PMC7732227</ArticleId><ArticleId IdType="pubmed">33316228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling C.-q. Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2) J. Integr. Med. 2020;18:87. doi: 10.1016/j.joim.2020.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joim.2020.02.004</ArticleId><ArticleId IdType="pmc">PMC7129043</ArticleId><ArticleId IdType="pubmed">32122812</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong-Zhi D., Xiao-Ying H., Yu-Huan M., Huang B.-S., Da-Hui L. Traditional Chinese Medicine: An effective treatment for 2019 novel coronavirus pneumonia (NCP) Chin. J. Nat. Med. 2020;18:206–210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270732</ArticleId><ArticleId IdType="pubmed">32245590</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng M., Wang X., Chen J., Qu R., Sui Y., Cizmas L., Wang Z., Sharma V.K. Degradation of fluoroquinolone antibiotics by ferrate (VI): Effects of water constituents and oxidized products. Water Res. 2016;103:48–57. doi: 10.1016/j.watres.2016.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.watres.2016.07.014</ArticleId><ArticleId IdType="pubmed">27429354</ArticleId></ArticleIdList></Reference><Reference><Citation>De Briyne N., Atkinson J., Borriello S., Pokludová L. Antibiotics used most commonly to treat animals in Europe. Vet. Rec. 2014;175:325. doi: 10.1136/vr.102462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/vr.102462</ArticleId><ArticleId IdType="pmc">PMC4215272</ArticleId><ArticleId IdType="pubmed">24899065</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman N., Chateau D., Dahl M., Zhang J., Fisher A., Sketris I.S., Quail J., Marra F., Ernst P., Bugden S. Fluoroquinolone use for uncomplicated urinary tract infections in women: A retrospective cohort study. Clin. Microbiol. Infect. 2020;26:613–618. doi: 10.1016/j.cmi.2019.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2019.10.016</ArticleId><ArticleId IdType="pubmed">31655215</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Zhao Y., Ren Z., Li Y. Combined QSAR/QSPR and molecular docking study on fluoroquinolones to reduce biological enrichment. Comput. Biol. Chem. 2019;79:177–184. doi: 10.1016/j.compbiolchem.2019.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiolchem.2019.02.008</ArticleId><ArticleId IdType="pubmed">30836319</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawczak P., Bober L., Bączek T. Application of QSAR analysis and different quantum chemical calculation methods in activity evaluation of selected fluoroquinolones. Comb. Chem. High Throughput Screen. 2018;21:468–475. doi: 10.2174/1386207321666180827105856.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1386207321666180827105856</ArticleId><ArticleId IdType="pubmed">30147010</ArticleId></ArticleIdList></Reference><Reference><Citation>Buglak A.A., Shanin I.A., Eremin S.A., Lei H.-T., Li X., Zherdev A.V., Dzantiev B.B. Ciprofloxacin and clinafloxacin antibodies for an immunoassay of quinolones: Quantitative structure–activity analysis of cross-reactivities. Int. J. Mol. Sci. 2019;20:265. doi: 10.3390/ijms20020265.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20020265</ArticleId><ArticleId IdType="pmc">PMC6359390</ArticleId><ArticleId IdType="pubmed">30641870</ArticleId></ArticleIdList></Reference><Reference><Citation>Scientifico-Disciplinare S., Falabella P., Luca F., Scrano L. Advanced Oxidation Processes (AOPs): Solutions for the degradation of emerging contaminants in liquid phases. Water. 2023;15:1615.</Citation></Reference><Reference><Citation>Appelbaum P., Hunter P. The fluoroquinolone antibacterials: Past, present and future perspectives. Int. J. Antimicrob. Agents. 2000;16:5–15. doi: 10.1016/S0924-8579(00)00192-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0924-8579(00)00192-8</ArticleId><ArticleId IdType="pubmed">11185413</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection. 2005;33((Suppl. 2)):55–70. doi: 10.1007/s15010-005-8209-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-005-8209-8</ArticleId><ArticleId IdType="pubmed">16518713</ArticleId></ArticleIdList></Reference><Reference><Citation>Kula K., Nagatsky R., Sadowski M., Siumka Y., Demchuk O.M. Arylcyanomethylenequinone Oximes: An Overview of Synthesis, Chemical Transformations, and Biological Activity. Molecules. 2023;28:5229. doi: 10.3390/molecules28135229.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28135229</ArticleId><ArticleId IdType="pmc">PMC10343898</ArticleId><ArticleId IdType="pubmed">37446890</ArticleId></ArticleIdList></Reference><Reference><Citation>Marciniec K., Beberok A., Pęcak P., Boryczka S., Wrześniok D. Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: Preliminary in silico analysis. Pharmacol. Rep. 2020;72:1553–1561. doi: 10.1007/s43440-020-00169-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-020-00169-0</ArticleId><ArticleId IdType="pmc">PMC7561236</ArticleId><ArticleId IdType="pubmed">33063271</ArticleId></ArticleIdList></Reference><Reference><Citation>Scroggs S.L., Offerdahl D.K., Flather D.P., Morris C.N., Kendall B.L., Broeckel R.M., Beare P.A., Bloom M.E. Fluoroquinolone antibiotics exhibit low antiviral activity against SARS-CoV-2 and MERS-CoV. Viruses. 2020;13:8. doi: 10.3390/v13010008.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010008</ArticleId><ArticleId IdType="pmc">PMC7822115</ArticleId><ArticleId IdType="pubmed">33374514</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary K.K., Mishra N.J.D. A review on molecular docking: Novel tool for drug discovery. JSM Chem. 2016;3:1029.</Citation></Reference><Reference><Citation>Santos E.S., Silva P.C., Sousa P.S.A., Aquino C.C., Pacheco G., Teixeira L.F.L.S., Araujo A.R., Sousa F.B.M., Barros R.O., Ramos R.M., et al. Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches. Chem. Biol. Interact. 2022;367:110161. doi: 10.1016/j.cbi.2022.110161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2022.110161</ArticleId><ArticleId IdType="pmc">PMC9476334</ArticleId><ArticleId IdType="pubmed">36116513</ArticleId></ArticleIdList></Reference><Reference><Citation>Barciszewska A.-M. Elucidating of oxidative distress in COVID-19 and methods of its prevention. Chem. Biol. Interact. 2021;344:109501. doi: 10.1016/j.cbi.2021.109501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2021.109501</ArticleId><ArticleId IdType="pmc">PMC8106523</ArticleId><ArticleId IdType="pubmed">33974898</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y.-L., Chen Y.-L., Sheu J.-Y., Chen I.-L., Wang T.-C., Tzeng C.-C., Chemistry M. Synthesis and antimycobacterial evaluation of certain fluoroquinolone derivatives. Bioorg. Med. Chem. 2005;13:3921–3926. doi: 10.1016/j.bmc.2005.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2005.04.005</ArticleId><ArticleId IdType="pubmed">15911308</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan S., Shafreen R.M.B., Nithyanand P., Manisankar P., Pandian S.K. Synthesis and in vitro antimicrobial evaluation of novel fluoroquinolone derivatives. Eur. J. Med. Chem. 2010;45:6101–6105. doi: 10.1016/j.ejmech.2010.09.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2010.09.036</ArticleId><ArticleId IdType="pubmed">20933306</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Trawneh S.A., El-Abadelah M.M., Al-Abadleh M.M., Zani F., Incerti M., Vicini P. A new efficient route to 7-aryl-6-fluoro-8-nitroquinolones as potent antibacterial agents. Eur. J. Med. Chem. 2014;86:364–367. doi: 10.1016/j.ejmech.2014.08.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2014.08.065</ArticleId><ArticleId IdType="pubmed">25180924</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhetri A., Chettri S., Rai P., Sinha B., Brahman D. Exploration of inhibitory action of Azo imidazole derivatives against COVID-19 main protease (Mpro): A computational study. J. Mol. Struct. 2021;1224:129178. doi: 10.1016/j.molstruc.2020.129178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molstruc.2020.129178</ArticleId><ArticleId IdType="pmc">PMC7456803</ArticleId><ArticleId IdType="pubmed">32904625</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X., Jing X., Wang J., Zheng Y., Qiu Y., Ji H., Peng L., Jiang S., Wu W., Guo D. Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19. Chem. Biol. Interact. 2022;361:109954. doi: 10.1016/j.cbi.2022.109954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2022.109954</ArticleId><ArticleId IdType="pmc">PMC9023373</ArticleId><ArticleId IdType="pubmed">35469826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye N., Yang Z., Liu Y. Applications of density functional theory in COVID-19 drug modeling. Drug Discov. Today. 2022;27:1411–1419. doi: 10.1016/j.drudis.2021.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2021.12.017</ArticleId><ArticleId IdType="pmc">PMC8695517</ArticleId><ArticleId IdType="pubmed">34954327</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Xie W., Xue X., Yang K., Ma J., Liang W., Zhao Q., Zhou Z., Pei D., Ziebuhr J. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005;3:e324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1197287</ArticleId><ArticleId IdType="pubmed">16128623</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science. 2003;300:1763–1767. doi: 10.1126/science.1085658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1085658</ArticleId><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaramillo P., Domingo L.R., Chamorro E., Pérez P. A further exploration of a nucleophilicity index based on the gas-phase ionization potentials. J. Mol. Struct. THEOCHEM. 2008;865:68–72. doi: 10.1016/j.theochem.2008.06.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.theochem.2008.06.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq S., Mutahir S., Khan M.A., Mutahir Z., Hussain S., Ashraf M., Bao X., Zhou B., Stark C.B.W., Khan I.U. Synthesis, in Vitro Cholinesterase Inhibition, Molecular Docking, DFT, and ADME Studies of Novel 1,3,4-Oxadiazole-2-Thiol Derivatives. Chem. Biodivers. 2022;19:e202200157. doi: 10.1002/cbdv.202200157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbdv.202200157</ArticleId><ArticleId IdType="pubmed">35767725</ArticleId></ArticleIdList></Reference><Reference><Citation>Celik S. DFT investigations and molecular docking as potent inhibitors of SARS-CoV-2 main protease of 4-phenylpyrimidine. J. Mol. Struct. 2023;1277:134895. doi: 10.1016/j.molstruc.2022.134895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molstruc.2022.134895</ArticleId><ArticleId IdType="pmc">PMC9803264</ArticleId><ArticleId IdType="pubmed">36619799</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakshminarayanan S., Jeyasingh V., Murugesan K., Selvapalam N., Dass G. Molecular electrostatic potential (MEP) surface analysis of chemo sensors: An extra supporting hand for strength, selectivity &amp; non-traditional interactions. J. Photochem. Photobiol. 2021;6:100022</Citation></Reference><Reference><Citation>Liu K., Lu X., Shi H., Xu X., Kong R., Chang S. nCoVDock2: A docking server to predict the binding modes between COVID-19 targets and its potential ligands. Nucleic Acids Res. 2023;51:W365–W371. doi: 10.1093/nar/gkad414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkad414</ArticleId><ArticleId IdType="pmc">PMC10320176</ArticleId><ArticleId IdType="pubmed">37194703</ArticleId></ArticleIdList></Reference><Reference><Citation>Alghamdi A., Abouzied A.S., Alamri A., Anwar S., Ansari M., Khadra I., Zaki Y.H., Gomha S.M. Synthesis, molecular docking, and dynamic simulation targeting main protease (Mpro) of new, Thiazole clubbed pyridine scaffolds as potential COVID-19 inhibitors. Curr. Issues Mol. Biol. 2023;45:1422–1442. doi: 10.3390/cimb45020093.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cimb45020093</ArticleId><ArticleId IdType="pmc">PMC9955078</ArticleId><ArticleId IdType="pubmed">36826038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatada R., Okuwaki K., Mochizuki Y., Handa Y., Fukuzawa K., Komeiji Y., Okiyama Y., Tanaka S. Fragment molecular orbital based interaction analyses on COVID-19 main protease—Inhibitor N3 complex (PDB ID: 6LU7) J. Chem. Inf. Model. 2020;60:3593–3602. doi: 10.1021/acs.jcim.0c00283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.0c00283</ArticleId><ArticleId IdType="pubmed">32539372</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M.A., Mutahir S., Jabar G., Wenwei Z., Tariq M.A., Almehizia A.A.A., Mustafa M. DFT, Molecular Docking, ADME, and Cardiotoxicity studies of Persuasive Thiazoles as Potential Inhibitors of the Main Protease of SARS-CoV-2. Chem. Biodivers. 2024:e202401775. doi: 10.1002/cbdv.202401775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbdv.202401775</ArticleId><ArticleId IdType="pubmed">39161231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseini F.S., Amanlou M. Simeprevir, potential candidate to repurpose for coronavirus infection: Virtual screening and molecular docking study. Life Sci. 2020;258:118205. doi: 10.1016/j.lfs.2020.118205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118205</ArticleId><ArticleId IdType="pmc">PMC7413873</ArticleId><ArticleId IdType="pubmed">32777300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S.-K.E., Wong W.C., Leung C.-W.R., Lai S.-T.T., Lo Y.-C.J., Wong K.-H.H., Chan M.-C., Que T.-L., Chow K.-W.M., Yuen M.-C., et al. Review of vector-borne diseases in Hong Kong. Travel Med. Infect. Dis. 2011;9:95–105. doi: 10.1016/j.tmaid.2010.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2010.01.004</ArticleId><ArticleId IdType="pubmed">21679886</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvelli J., Demaria O., Vély F., Batista L., Benmansour N.C., Fares J., Carpentier S., Thibult M.-L., Morel A., André P. Identification of immune checkpoints in COVID-19. 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-27340/v1</ArticleId><ArticleId IdType="pmc">PMC7327215</ArticleId><ArticleId IdType="pubmed">32612152</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Zhou Q., Li Y., Garner L.V., Watkins S.P., Carter L.J., Smoot J., Gregg A.C., Daniels A.D., Jervey S. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent. Sci. 2020;6:315–331. doi: 10.1021/acscentsci.0c00272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.0c00272</ArticleId><ArticleId IdType="pmc">PMC10467574</ArticleId><ArticleId IdType="pubmed">32226821</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivasankarapillai V.S., Pillai A.M., Rahdar A., Sobha A.P., Das S.S., Mitropoulos A.C., Mokarrar M.H., Kyzas G.Z.J.N. On facing the SARS-CoV-2 (COVID-19) with combination of nanomaterials and medicine: Possible strategies and first challenges. Nanomaterials. 2020;10:852. doi: 10.3390/nano10050852.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nano10050852</ArticleId><ArticleId IdType="pmc">PMC7712148</ArticleId><ArticleId IdType="pubmed">32354113</ArticleId></ArticleIdList></Reference><Reference><Citation>Owis A.I., El-Hawary M.S., El Amir D., Aly O.M., Abdelmohsen U.R., Kamel M.S.J.R.A. Molecular docking reveals the potential of Salvadora persica flavonoids to inhibit COVID-19 virus main protease. RSC Adv. 2020;10:19570–19575. doi: 10.1039/D0RA03582C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0RA03582C</ArticleId><ArticleId IdType="pmc">PMC9054211</ArticleId><ArticleId IdType="pubmed">35515460</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutahir S., Khan M.A., Naglah A.M., Al-Omar M.A., Almehizia A.A., Huwaimel B., Abouzied A.S., Alharbi A.S., Refat M.S. Structural Characterization and Molecular Docking Screening of Most Potent 1, 2, 4-Triazine Sulfonamide Derivatives as Anti-Cancer Agents. Crystals. 2023;13:767. doi: 10.3390/cryst13050767.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cryst13050767</ArticleId></ArticleIdList></Reference><Reference><Citation>Arshad R., Khan M.A., Mutahir S., Hussain S., Al-Hazmi G.H., Refat M.S. DFT, Molecular Docking and ADME Studies of Thiazolidinones as Tyrosinase Inhibitors. Polycycl. Aromat. Compd. 2022;43:6750–6765. doi: 10.1080/10406638.2022.2124286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10406638.2022.2124286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl A.S., Verma V.K., Bhatia J., Arya D.S. Integrating in silico and in vivo approach for investigating the role of polyherbal oil in prevention and treatment of COVID-19 infection. Chem. Biol. Interact. 2022;367:110179. doi: 10.1016/j.cbi.2022.110179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2022.110179</ArticleId><ArticleId IdType="pmc">PMC9472470</ArticleId><ArticleId IdType="pubmed">36113631</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg S., Roy A. In silico analysis of selected alkaloids against main protease (Mpro) of SARS-CoV-2. Chem. Biol. Interact. 2020;332:109309. doi: 10.1016/j.cbi.2020.109309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2020.109309</ArticleId><ArticleId IdType="pmc">PMC7649659</ArticleId><ArticleId IdType="pubmed">33181114</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao H.P., Wang T.H., Zhai H.L., Bi K.X., Zhao B.Q. Discovery of inhibitors against SARS-CoV-2 main protease using fragment-based drug design. Chem. Biol. Interact. 2023;371:110352. doi: 10.1016/j.cbi.2023.110352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2023.110352</ArticleId><ArticleId IdType="pmc">PMC9837207</ArticleId><ArticleId IdType="pubmed">36642317</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazeer U., Rasool N., Mujahid A., Mansha A., Zubair M., Kosar N., Mahmood T., Raza Shah A., Shah S.A.A., Zakaria Z.A. Selective arylation of 2-bromo-4-chlorophenyl-2-bromobutanoate via a Pd-catalyzed Suzuki cross-coupling reaction and its electronic and non-linear optical (NLO) properties via DFT studies. Molecules. 2020;25:3521. doi: 10.3390/molecules25153521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25153521</ArticleId><ArticleId IdType="pmc">PMC7435822</ArticleId><ArticleId IdType="pubmed">32752125</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliveisi R., Taherpour A., Yavari I. A DFT Study of Electronic Structures and Relative Stabilities of Isomeric n, m-Diazaphenanthrenes. Polycycl. Aromat. Compd. 2019;39:462–469. doi: 10.1080/10406638.2017.1343195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10406638.2017.1343195</ArticleId></ArticleIdList></Reference><Reference><Citation>Mebi C.A. DFT study on structure, electronic properties, and reactivity of cis-isomers of [(NC5H4S)2 Fe(CO)2] J. Chem. Sci. 2011;123:727–731. doi: 10.1007/s12039-011-0131-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12039-011-0131-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Orio M., Pantazis D.A., Neese F. Density functional theory. Photosynth. Res. 2009;102:443–453. doi: 10.1007/s11120-009-9404-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11120-009-9404-8</ArticleId><ArticleId IdType="pmc">PMC2777204</ArticleId><ArticleId IdType="pubmed">19238578</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutahir S., Khan M.A., Almehizia A.A., Abouzied A.S., Khalifa N.E., Naglah A.M., Deng H., Refat M.S., Khojali W.M., Huwaimel B. Design, Synthesis, Characterization and Computational Studies of Mannich Bases Oxadiazole Derivatives as New Class of Jack Bean Urease Inhibitors. Chem. Biodivers. 2023;20:e202300241. doi: 10.1002/cbdv.202300241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbdv.202300241</ArticleId><ArticleId IdType="pubmed">37344354</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadlalla M., Ahmed M., Ali M., Elshiekh A.A., Yousef B.A. Molecular docking as a potential approach in repurposing drugs against COVID-19: A systematic review and novel pharmacophore models. Curr. Pharmacol. Rep. 2022;8:212–226. doi: 10.1007/s40495-022-00285-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40495-022-00285-w</ArticleId><ArticleId IdType="pmc">PMC8970976</ArticleId><ArticleId IdType="pubmed">35381996</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutahir S., Khan M.A., Khan I.U., Yar M., Ashraf M., Tariq S., Ye R.-L., Zhou B.-J. Organocatalyzed and mechanochemical solvent-free synthesis of novel and functionalized bis-biphenyl substituted thiazolidinones as potent tyrosinase inhibitors: SAR and molecular modeling studies. Eur. J. Med. Chem. 2017;134:406–414. doi: 10.1016/j.ejmech.2017.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2017.04.021</ArticleId><ArticleId IdType="pubmed">28433680</ArticleId></ArticleIdList></Reference><Reference><Citation>Daina A., Michielin O., Zoete V.J.S.r. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017;7:42717. doi: 10.1038/srep42717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42717</ArticleId><ArticleId IdType="pmc">PMC5335600</ArticleId><ArticleId IdType="pubmed">28256516</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikiewicz A., Banach M., von Haehling S., Maciejewski M., Bielecka-Dabrowa A.J.E.H.F. Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications. ESC Heart Fail. 2021;8:2397–2418. doi: 10.1002/ehf2.13365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13365</ArticleId><ArticleId IdType="pmc">PMC8318493</ArticleId><ArticleId IdType="pubmed">33955207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>